EPA 및 DHA 시장 보고서 : 유형, 원료, 용도, 지역별(2026-2034년)

The global EPA & DHA market size reached USD 2,104.4 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 3,455.5 Million by 2034, exhibiting a growth rate (CAGR) of 5.50% during 2026-2034. The increasing consumer awareness about the health benefits of omega-3 fatty acids, rising demand for functional foods and supplements, and the growing prevalence of sustainable and eco-friendly sourcing practices in the fishing industry represent some of the key factors driving the market.

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) refer to long-chain polyunsaturated omega-3 fatty acids with similar chemical structures that are essential for human health. Usually found in fatty fish, such as salmon, mackerel, sardines and algae, EPA and DHA are not synthesized by the human body and must be obtained through diet or supplementation. EPA and DHA from fish and supplements are highly bioavailable, therefore they are absorbed by the human body relatively easily and can be incorporated into cell membranes and other structures where they are needed. EPA and DHA are important for brain function and development as they protect against cognitive decline and their anti-inflammatory properties help to reduce the risk of chronic diseases, such as heart disease, cholesterol, and arthritis. In addition to this, EPA and DHA are important for regulating the immune system, benefitting skin health and minimizing the risks of age-related macular degeneration.

EPA & DHA MARKET TRENDS:

The global market is majorly driven by the augmenting demand for supplements and functional foods containing EPA and DHA. This can be attributed to the rising incidences of chronic diseases, such as heart disease, diabetes, and cancer among the masses, particularly the geriatric population. In line with this, the increasing awareness among consumers regarding health and fitness is also propelling the demand for EPA and DHA fortified foods. Moreover, the increasing usage of EPA and DHA in infant formula and pet food is creating lucrative growth opportunities in the market. Besides this, continual technological advancements in the processing techniques enabling manufacturers to produce high-purity and high-concentration EPA and DHA supplements and functional foods are providing an impetus to the market. The growing adoption of plant-based vegan diets among the consumer base is resulting in a higher uptake of plant-based sources of EPA and DHA, such as algae-based supplements and foods. The market is further fueled by the paradigm shift in regulations and labeling requirements for food and supplements, resulting in companies adjusting their formulations and marketing strategies to comply with new rules. Some of the other factors contributing to the market include rapid urbanization, growing prevalence of sustainable and eco-friendly sourcing practices in the fishing industry, inflating disposable income levels, and extensive research and development (R&D) activities conducted by the key players.

KEY MARKET SEGMENTATION:

Type Insights:

• Eicosapentaenoic Acid (EPA)
• Docosahexaenoic Acid (DHA)

Source Insights:

• Fish Oil
• Algae Oil
• Krill Oil
• Others

Application Insights:

• Infant Formulae
• Dietary Supplements
• Fortified Food and Beverages
• Pharmaceuticals
• Others

Regional Insights:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific was the largest market for EPA & DHA. Some of the factors driving the Asia Pacific EPA & DHA market included the growing geriatric population, continual technological advancements in sustainable fishing practices, increasing awareness regarding health and fitness, etc.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global EPA & DHA market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AlgiSy BioSciences Inc., Arctic Nutrition AG, BASF SE, Biosearch Sau, Corbion NV, Croda International PLC, KD Pharma Group, Koninklijke DSM NV, Nordic Naturals Inc, Novasep Holding SAS, Novotech Nutraceuticals Inc, Omega Protein Corporation, Polaris, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the global EPA & DHA market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global EPA & DHA market?
• What is the impact of each driver, restraint, and opportunity on the global EPA & DHA market?
• What are the key regional markets?
• Which countries represent the most attractive EPA & DHA market?
• What is the breakup of the market based on the type?
• Which is the most attractive type in the EPA & DHA market?
• What is the breakup of the market based on the source?
• Which is the most attractive source in the EPA & DHA market?
• What is the breakup of the market based on application?
• Which is the most attractive application in the EPA & DHA market?
• What is the competitive structure of the global EPA & DHA market?
• Who are the key players/companies in the global EPA & DHA market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global EPA & DHA Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Eicosapentaenoic Acid (EPA)
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Docosahexaenoic Acid (DHA)
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Source

• 7.1 Fish Oil
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Algae Oil
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Krill Oil
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Application

• 8.1 Infant Formulae
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Dietary Supplements
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Fortified Food and Beverages
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Pharmaceuticals
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AlgiSy BioSciences Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Arctic Nutrition AG
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 BASF SE
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Biosearch Sau
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Corbion NV
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
  • 14.3.6 Croda International PLC
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 KD Pharma Group
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Koninklijke DSM NV
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Nordic Naturals Inc
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Novasep Holding SAS
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Novotech Nutraceuticals Inc
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 SWOT Analysis
  • 14.3.12 Omega Protein Corporation
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
  • 14.3.13 Polaris
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio